Literature DB >> 17101779

Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma.

Elke Burgermeister1, Dana Chuderland, Tamar Hanoch, Markus Meyer, Mordechai Liscovitch, Rony Seger.   

Abstract

The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) cascade plays a central role in intracellular signaling by many extracellular stimuli. One target of the ERK cascade is peroxisome proliferator-activated receptor gamma (PPARgamma), a nuclear receptor that promotes differentiation and apoptosis. It was previously demonstrated that PPARgamma activity is attenuated upon mitogenic stimulation due to phosphorylation of its Ser84 by ERKs. Here we show that stimulation by tetradecanoyl phorbol acetate (TPA) attenuates PPARgamma's activity in a MEK-dependent manner, even when Ser84 is mutated to Ala. To elucidate the mechanism of attenuation, we found that PPARgamma directly interacts with MEKs, which are the activators of ERKs, but not with ERKs themselves, both in vivo and in vitro. This interaction is facilitated by MEKs' phosphorylation and is mediated by the basic D domain of MEK1 and the AF2 domain of PPARgamma. Immunofluorescence microscopy and subcellular fractionation revealed that MEK1 exports PPARgamma from the nucleus, and this finding was supported by small interfering RNA knockdown of MEK1 and use of a cell-permeable interaction-blocking peptide, which prevented TPA-induced export of PPARgamma from the nucleus. Thus, we show here a novel mode of downregulation of PPARgamma by its MEK-dependent redistribution from the nucleus to the cytosol. This unanticipated role for the stimulation-induced nuclear shuttling of MEKs shows that MEKs can regulate additional signaling components besides the ERK cascade.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101779      PMCID: PMC1800691          DOI: 10.1128/MCB.00601-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  47 in total

1.  ERK1b, a 46-kDa ERK isoform that is differentially regulated by MEK.

Authors:  Y Yung; Z Yao; T Hanoch; R Seger
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

2.  Hydrophobic as well as charged residues in both MEK1 and ERK2 are important for their proper docking.

Authors:  S Stippec; F L Robinson; M H Cobb
Journal:  J Biol Chem       Date:  2001-05-14       Impact factor: 5.157

3.  Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation.

Authors:  M L Lu; M C Schneider; Y Zheng; X Zhang; J P Richie
Journal:  J Biol Chem       Date:  2001-01-18       Impact factor: 5.157

Review 4.  The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions.

Authors:  Seunghee Yoon; Rony Seger
Journal:  Growth Factors       Date:  2006-03       Impact factor: 2.511

5.  Involvement of the activation loop of ERK in the detachment from cytosolic anchoring.

Authors:  I Wolf; H Rubinfeld; S Yoon; G Marmor; T Hanoch; R Seger
Journal:  J Biol Chem       Date:  2001-04-27       Impact factor: 5.157

6.  Nuclear translocation of mitogen-activated protein kinase kinase (MEK1) in response to mitogenic stimulation.

Authors:  H Jaaro; H Rubinfeld; T Hanoch; R Seger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

7.  A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus.

Authors:  J Berger; H V Patel; J Woods; N S Hayes; S A Parent; J Clemas; M D Leibowitz; A Elbrecht; R A Rachubinski; J P Capone; D E Moller
Journal:  Mol Cell Endocrinol       Date:  2000-04-25       Impact factor: 4.102

8.  Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo.

Authors:  A Ho; S R Schwarze; S J Mermelstein; G Waksman; S F Dowdy
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

9.  Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7.

Authors:  D Chen; T Riedl; E Washbrook; P E Pace; R C Coombes; J M Egly; S Ali
Journal:  Mol Cell       Date:  2000-07       Impact factor: 17.970

10.  Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists.

Authors:  H Sato; S Ishihara; K Kawashima; N Moriyama; H Suetsugu; H Kazumori; T Okuyama; M A Rumi; R Fukuda; N Nagasue; Y Kinoshita
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

View more
  77 in total

Review 1.  General molecular biology and architecture of nuclear receptors.

Authors:  Michal Pawlak; Philippe Lefebvre; Bart Staels
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

2.  Growth hormone controls lipolysis by regulation of FSP27 expression.

Authors:  Rita Sharma; Quyen Luong; Vishva M Sharma; Mitchell Harberson; Brian Harper; Andrew Colborn; Darlene E Berryman; Niels Jessen; Jens Otto Lunde Jørgensen; John J Kopchick; Vishwajeet Puri; Kevin Y Lee
Journal:  J Endocrinol       Date:  2018-12-01       Impact factor: 4.286

3.  Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Authors:  A A Martinez; M G Morgese; A Pisanu; T Macheda; M A Paquette; A Seillier; T Cassano; A R Carta; A Giuffrida
Journal:  Neurobiol Dis       Date:  2014-12-05       Impact factor: 5.996

4.  Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.

Authors:  Ulf Lützen; Yi Zhao; Katja Lucht; Maaz Zuhayra; Marlies Marx; Ingolf Cascorbi; Juraj Culman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-23       Impact factor: 3.000

5.  Nuclear translocation of MEK1 triggers a complex T cell response through the corepressor silencing mediator of retinoid and thyroid hormone receptor.

Authors:  Lei Guo; Chaoyu Chen; Qiaoling Liang; Mohammad Zunayet Karim; Magdalena M Gorska; Rafeul Alam
Journal:  J Immunol       Date:  2012-12-05       Impact factor: 5.422

6.  An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

Authors:  Georg Hansmann; Vinicio A de Jesus Perez; Tero-Pekka Alastalo; Cristina M Alvira; Christophe Guignabert; Janine M Bekker; Stefan Schellong; Takashi Urashima; Lingli Wang; Nicholas W Morrell; Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

7.  Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock.

Authors:  Ranjit S Chima; Paul W Hake; Giovanna Piraino; Prajakta Mangeshkar; Alvin Denenberg; Basilia Zingarelli
Journal:  Crit Care Med       Date:  2008-10       Impact factor: 7.598

8.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

Review 9.  From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.

Authors:  Christophe Frémin; Sylvain Meloche
Journal:  J Hematol Oncol       Date:  2010-02-11       Impact factor: 17.388

10.  The PPARgamma2 A/B-domain plays a gene-specific role in transactivation and cofactor recruitment.

Authors:  Anne Bugge; Lars Grøntved; Mads M Aagaard; Rehannah Borup; Susanne Mandrup
Journal:  Mol Endocrinol       Date:  2009-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.